The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

Good Morning Washington recently sat down with Dr. Patel, a double board-certified physician from Physicians Premiere Weight ...

Agency will require a Limitation of Use section in the prescribing information of all extended-release ADHD stimulants.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Once everyone’s had enough of injections, side effects, and the vast expense of GLP-1 drugs, it could be natural alternatives ...

Instant ramen maker Nissin Foods is leveraging the buzz around GLP-1s to launch in the US a trio of decadent tasting frozen ...

The U.S. Food and Drug Administration is revising the labeling of all extended-release attention-deficit/hyperactivity ...

In the pursuit of health and wellness, the modern consumer is constantly on the lookout for effective, natural solutions that ...

We view a Medifast revitalization as hinging on a steep coach network inflection. Read why we think MED stock becomes a core ...

A clinical trial for semaglutide, the active ingredient in Ozempic, found that it improved blood sugar control in people with ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...